Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
Phase 1
Completed
- Conditions
- COVID-19 PositiveInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12621000034831
- Lead Sponsor
- Firebrick Pharma Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Adult (18+ years old) patients with
(a) confirmed COVID-19 symptoms and
(b) symptom onset within the past five days.
Exclusion Criteria
• Known iodine sensitivity
• Previously diagnosed thyroid disease
• Previously diagnosed kidney disease
• Known to be pregnant or currently breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method